المؤلفون: Inge Ludwig, Ellen van der Spek, Paul A F Geerts, Pieter Sonneveld, Margriet Oosterveld, Yavuz M. Bilgin, Savita Soechit, Niels W.C.J. van de Donk, Noortje Thielen, Nicole C H P de Graauw, Mark-David Levin, Gert Jan Timmers, Inger S. Nijhof, Kazem Nasserinejad, Alain Kentos, Marjolein van der Klift, Claudia A.M. Stege, Saskia K. Klein, Esther G.M. De Waal, Matthijs H Silbermann, Maaike Sohne, Marie-Christiane Vekemans, Sonja Zweegman, Roel J.W. van Kampen, Nazik Durdu-Rayman

المساهمون: UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Internal medicine, Hematology, CCA - Cancer Treatment and quality of life

المصدر: Journal of clinical oncology, Vol. 39, no. 25, p. 2758-2767 (2021)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(25), 2758-2767. American Society of Clinical Oncology
Stege, C A M, Nasserinejad, K, van der Spek, E, Bilgin, Y M, Kentos, A, Sohne, M, van Kampen, R J W, Ludwig, I, Thielen, N, Durdu-Rayman, N, de Graauw, N C H P, van de Donk, N W C J, de Waal, E G M, Vekemans, M C, Timmers, G J, van der Klift, M, Soechit, S, Geerts, P A F, Silbermann, M H, Oosterveld, M, Nijhof, I S, Sonneveld, P, Klein, S K, Levin, M D & Zweegman, S 2021, ' Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma : The Hovon 143 Study ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 25, pp. 2758-2767 . https://doi.org/10.1200/JCO.20.03143

مصطلحات موضوعية: Oncology, Boron Compounds, Male, Cancer Research, medicine.medical_specialty, Frail Elderly, Glycine, Dexamethasone, Ixazomib, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Prospective Studies, Prospective cohort study, Survival rate, Multiple myeloma, Aged, Aged, 80 and over, business.industry, Daratumumab, Antibodies, Monoclonal, medicine.disease, Prognosis, Discontinuation, Clinical trial, Survival Rate, chemistry, 030220 oncology & carcinogenesis, Quality of Life, Female, business, Multiple Myeloma, 030215 immunology, medicine.drug, Follow-Up Studies

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bd16999f1d8f8fc2bbefd1520cedee3
https://hdl.handle.net/2078.1/261917